Biochemical Engineering Special Interest Group
biological engineering professionals
20 June 2017

Cell Medica buys clinical-phase WT1-TCR cell therapy

Cell Medica has bought Catapult Therapy TCR for its clinical-phase WT1 T-cell receptor (TCR) cell therapy. Catapult Therapy TCR developed the therapy as a treatment for blood cancers, but Cell Medica thinks it can retool it to take out solid tumors. The British biotech plans to apply the Dominant TCR technology it licensed from UCL last year to the cell therapy to equip it to treat solid tumors. The technology is designed to increase the efficacy of engineered T cells by dialing up the expression of TCRs. Source: Fierce Biotech 20/6/2017

My IChemE

IChemE is a registered charity in England & Wales (214379), and a charity registered in Scotland (SC 039661).